We have previously demonstrated that delivery of EphA2 siRNA through 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine (DOPC) neutral liposome nanoparticles (EPHARNA) showed highly efficient in vivo delivery to the tumor, resulting in decreased tumor burden in mouse ovarian cancer models [13]. The gene discussed is EPHA2; the disease is ovarian cancer.